BioWorld® - Medical Device Daily

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information
Cartesian Technology Inc.--U.S.
Genomic Solutions Ltd.--U.K.
Genomic Solutions Canada Inc.--U.S.
Genomic Solutions Inc.--Canada
Hoefer Inc.--U.S.
KDS Inc.--U.S.
BUSINESS STRATEGY: Have a broad range of specialized products that hold strong positions in
niche markets focused on the bottlenecks in drug discovery research in
order to reduce the risk of being dependent on a single technology, to
reduce head-to-head competition; and to position ourselves to achieve
above-average revenue growth and above-average margins
RESEARCH & DEVELOPMENT: Focus is on the development of products that address bottlenecks within the
drug discovery process, in particular, for application in the areas of ADMET
screening, molecular biology, genomics, proteomics and highthroughput/high-content
screening
PRODUCTS ON MARKET: ADMET screening products, including absorption diffusion chambers, 96
well equilibrium dialysis plate for serum protein binding assays, organ
testing systems, precision infusion pumps, cell injection systems, ventilators,
electroporation products
Molecular biology products, including spectrophotometers;
DNA/RNA/Protein calculators; multi-well plate readers; amino acid analysis
systems; low volume, high-throughput liquid dispensers; gel electrophoresis
systems
Hawaii Biotech Inc.
99-193 Aiea Heights Drive, Suite 200
Aiea HI 96701, US
Phone: (808) 486-5333; Fax: (808) 792-1343
Web: www.hibiotech.com
E-mail: info@hibiotech.com
KEY PERSONNEL: Nicholas Mitsakos; Chairman
David G. Watumull; President and CEO
Samuel F. Lockwood, M.D.; Medical Director
Carolyn Weeks-Levy, Ph.D.; VP, Research, Preclinical Development and
Regulatory Affairs
Richard L. Sherman; Sr. VP, Business Development and General Counsel
EMPLOYEES: 60 employees, 8 Ph.D.s
HISTORY: Founded in 1982
Began biotech R&D in 1983
Merged vaccine business with Avantogen Ltd.'s vaccine business (5/06)
Member--Biotechnology Industry Organization
FACILITIES: 9,000 sq. ft. headquarters and R&D facility
STOCK-FINANCIAL HISTORY: Privately held
PRIVATE PLACEMENTS: Raised $8.5M in Series A financing
Raised $4M in federal funding (2003)
Raised $8M (2004)
Raised $7.8M in Series C financing (1/06)
INVESTMENTS: PanThera Biopharma Inc.
FINANCIAL INFORMATION: Received $15.5M through three awards from the NIH for West Nile Virus
and dengue vaccine development (12/04)
Copyright ©2006 AHC Media ® 183